ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OSTX vs FBIO // ALTMAN Z-SCORE & DEBT/EQUITY

OS Therapies Incorporated (NYSE) VS. Fortress Biotech Inc. (NASDAQ) • 15-METRIC TALLY: OSTX 1 — FBIO 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OSTX VS. FBIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OSTX FBIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 66.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -21.07% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — 58.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 9.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 1.00% -1.00 FBIO /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 FBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.8 38.7 -4.85 FBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $67.6M $66.7M $882.5K OSTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OSTX REV FBIO REV OSTX GROSS % FBIO GROSS % OSTX FCF FBIO FCF
FY 2025 $0 $63.3M — 66.9% -$14.2M -$65.8M
FY 2024 $0 $57.7M — 63.8% -$7.3M -$80.2M
FY 2023 $0 $84.5M — — -$3.0M -$128.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OSTX // BETA —
FBIO // BETA —